文献速递肝病食管胃疾病与幽门螺杆菌

非酒精性脂肪性肝病及肝纤维化与心血管事件风险增加相关:一项前瞻性研究

Nonalcoholic Fatty Liver Disease and Fibrosis Associated With Increased Risk of Cardiovascular Events in a Prospective Study.
PubMed 文献 · Clin Gastroenterol Hepatol · 2019-12-27

该前瞻性观察研究纳入898例连续门诊患者,中位随访41.4个月,记录58例心血管事件(1.9%/年)。

要点

  • NAFLD患者心血管事件风险较无NAFLD者增加2倍以上。
  • NAFLD合并肝纤维化(FIB-4>2.67)者心血管事件风险增加约4倍。
  • NAFLD患者中肝纤维化指标独立预测心血管事件。

核心结论

  • NAFLD患者心血管事件风险较无NAFLD者增加2倍以上,合并肝纤维化者风险增加约4倍。
  • 在NAFLD患者中,肝纤维化指标(FIB-4>2.67和NFS>0.676)与心血管事件风险独立相关。

研究设计与样本

  • 前瞻性观察研究,纳入898例连续门诊患者(平均年龄56.4±12.7岁,女性37.5%),按Hamaguchi标准经超声筛查肝脂肪变。
  • 肝纤维化定义为FIB-4评分>2.67和NAFLD纤维化评分>0.676。
  • 入组后每6个月电话随访、每12个月门诊检查,记录心血管事件;中位随访41.4个月(3044.4患者年)。

主要发现

  • 随访期间共记录58例心血管事件(1.9%/年)。

关键数值与推荐

  • 肝纤维化判定:FIB-4评分>2.67和NAFLD纤维化评分>0.676。

临床怎么用

  • 对NAFLD患者应评估肝纤维化指标(FIB-4、NFS)以识别心血管事件高风险人群。
  • NAFLD合并肝纤维化者需加强心血管风险监测与管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Patients with non-alcoholic fatty liver disease (NAFLD) are at increased chance for cardiovascular events (CVEs). Severity of liver fibrosis is used to determine prognoses for patients with NAFLD, but little is known about the relationship between liver fibrosis and CVEs in the real world. METHODS: We analyzed data from the prospective observational progression of liver damage and cardiometabolic disorders in non-alcoholic fatty liver disease study, comprising 898 consecutive outpatients (mean age, 56.4 ± 12.7 years; 37.5% women) screened for liver steatosis by ultrasound according to Hamagughi criteria. Liver fibrosis was defined as FIB-4 score greater than 2.67 and NAFLD fibrosis score greater than 0.676. After enrolment, patients were interviewed by phone every 6 months and examined every 12 months in the outpatient clinic, and CVEs were recorded (fatal or nonfatal ischemic stroke and myocardial infarction, cardiac or peripheral revascularization, new-onset arterial fibrillation and cardiovascular death). The primary outcomes were incidence rate of CVEs in patients with vs without NAFLD and factors associated with CVEs in patients with NAFLD. RESULTS: Over a median follow-up time of 41.4 months (3044.4 patient-years), 58 CVEs (1.9%/year) were registered. The rate of CVEs was higher in patients with (n = 643, 2.1%/year) vs without NAFLD (n = 255, 1.0%/year) (P = .066). In multivariable Cox proportional regression analysis, NAFLD increased risk for CVEs (hazard ratio [HR], 2.41; 95% CI, 1.06-5.47; P = .036), after adjustment for metabolic syndrome. Among patients with NAFLD, male sex, previous CVEs, metabolic syndrome and FIB-4 scores greater than 2.67 (HR, 4.02; 95% CI, 1.21-13.38; P = .023) were independently associated with risk of incident CVEs. NFS scores greater than 0.676 were also independently associated with risk of incident CVEs (HR, 2.35; 95% CI, 1.05-5.27; P = .038). CONCLUSIONS: In an analysis of data from a study of patients screened for NAFLD and followed, individuals with NAFLD had more than a 2-fold increase in risk of CVEs, and those with liver fibrosis had a 4-fold increase in risk. In patients with NAFLD, liver fibrosis indexes were independently associated with risk of incident CVEs. ClinicalTrials.gov no:NCT04036357.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Baratta F, Pastori D, Angelico F, et al. Nonalcoholic Fatty Liver Disease and Fibrosis Associated With Increased Risk of Cardiovascular Events in a Prospective Study. Clin Gastroenterol Hepatol. 2019. PMID: 31887443. doi:10.1016/j.cgh.2019.12.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。